Medis launches 37.8 million Telmisartan HCT in 8 European markets
Medis launched Telmisartan HCT on patent expiry, 12th December 2013, with 15 customers in 8 European markets. The scope of the launch can best be described as very complex and it took the manufacturing site a total of 10 weeks to produce the 37.8 million tablets before launch.
Telmisartan HCT is intended for treatment of essential hypertension and is the generic equivalent of Boehringer Ingelheim’s brand, MicardisPlus®. The tablet, delivering both telmisartan and hydrochlorothiazide, works in two different ways when treating high blood pressure. It is a combination of angiotensin II receptor antagonist with the thiazide diuretic hydrochlorothiazide.
Initial development of Telmisartan HCT began in Iceland in 2006, in combination with the development of Telmisartan mono, and registration work started in early 2012. In order to obtain Marketing Authorizations as soon as possible, this project was given top priority by our regulatory specialists.